Menopause? Meet the award-winning private pharmacy throwing menopausal women a lifeline

Remedi Health's end-to-end menopause service is proving community pharmacy’s clinical credentials to the people of Winchester

event
Remedi Health took home the prize for Health Initiative of the Year at the C+D Awards 2023 (PHILIPPA_GEDGE)

The historic city of Winchester is perhaps best-known for its medieval cathedral, picturesque streets and the Winchester City Mill. But a local pharmacy and healthcare clinic is putting this genteel corner of Hampshire on the map for other reasons. Its mould-breaking private model and service-led approach has patients flocking to be seen.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

Latest from Analysis

Why I’ve launched a campaign against the RPS’s planned changes

 
• By 
 • comment7

‘Vote no’ campaigner Martin Astbury tells C+D why he believes the RPS plans for change represent a shift away from pharmacist leadership and why members should vote against them this week…

CPE is negotiating in a very difficult and nuanced environment that few will have experienced

 
• By 
 • comment12

I also read comments that CPE does not appreciate this critical position, and I fundamentally refute that. Knowing the colleagues, both elected and employed, at CPE as I do, this is far from the case.

It’s not just funding delays holding pharmacy back, it’s the old dinosaurs too...

 
• By 
 • comment7

Community pharmacy is risk adverse, considered, and dare I say it, conservative. But, when it comes to the survival of pharmacy, we can’t afford to let the fear of change – or those resistant to it - hold us back.

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment8

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment2

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.